Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04501978 | ACTIV-3: Therapeutics for Inpatients With COVID-19 | PHASE3 | COMPLETED | 2,753 | — | — | Aug 4, 2020 | Jul 14, 2023 | Aug 25, 2023 | 135 | United States, Denmark +8 |
Sustained recovery defined as being discharged from the index hospitalization, followed by being alive and home for 14 consecutive days prior to Day 90.
| Arm | Type | Description |
|---|---|---|
| ACTIV-3 Drug plus SOC | EXPERIMENTAL | Participants in this study will be randomized to receive one of the ACTIV-3 drug treatments plus Standard of Care (SOC) or placebo plus SOC |
| Placebo plus SOC | PLACEBO_COMPARATOR | The placebo arm may be pooled across more than one experimental arm if multiple investigational drugs are available to be tested at the same time. If it is not possible to use matching placebo over more than one experimental arm, additional placebo arms will be included in the study |
| Name | Type | Description |
|---|---|---|
| LY3819253 | BIOLOGICAL | Participants are no longer being randomized to this intervention. |
| Placebo | DRUG | Commercially available 0.9% sodium chloride solution. Administered by IV infusion |
| Remdesivir | BIOLOGICAL | Provided to all study participants as SOC unless contraindicated for an individual patient. |
| VIR-7831 | BIOLOGICAL | Participants are no longer being randomized to this intervention. |
| BRII-196/BRII-198 | BIOLOGICAL | Participants are no longer being randomized to this intervention. |
| AZD7442 | BIOLOGICAL | Participants are no longer being randomized to this intervention. |
| MP0420 | DRUG | Participants are no longer being randomized to this intervention. |
| PF-07304814 | DRUG | 250 mg per day for 5 days. Administered as a constant rate intravenous infusion. Suspended: Participants are not currently being randomized to this intervention. |
Inclusion Criteria: * Signed informed consent. * Positive test for COVID-19 and progressive disease suggestive of ongoing COVID-19 infection. * Symptoms of COVID-19 for ≤ 12 days. * Require admission to hospital for acute medical care (not for purely public health or quarantine purposes). Exclusio...